Assessment of the efficacy, tolerability and pharmaco-economic impact of zoledronic acid treatment in prostate cancer with bone metastasis
Phase of Trial: Phase IV
Latest Information Update: 08 Mar 2017
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Cancer metastases; Prostate cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 06 Apr 2010 Actual number of patients (148) added and primary outcomes amended as reported by ClinicalTrials.gov record.
- 06 Apr 2010 Actual end date (1 Jan 2006) added as reported by ClinicalTrials.gov record.
- 06 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.